Tarsier Pharma Ltd (Ticker: TARX US) is an Israeli Phase 3 biotechnology company developing steroid-free therapies for autoimmune and inflammatory eye diseases that can cause blindness. The company’s lead drug candidates are based on dazdotuftide and include TRS01, an eye drop, and TRS02, an injectable therapy, targeting non-infectious anterior uveitis and other ocular inflammatory conditions.

Tarsier Pharma plans to list on the NYSE American on July 9, 2026. According to published terms, the company plans to offer 5.0 million common shares at an expected price range of $8.00 to $10.00 per share, raising approximately $45 million at the midpoint, with a 15% greenshoe option for 750,000 additional shares. The IPO consists of 100% primary shares. The estimated market capitalization at the offering is approximately $294 million. Konik Capital Partners, a division of T.R. Winston, is acting as manager of the offering.